Eloralintide for knee osteoarthritis pain in adults who are overweight or have obesity
Tests eloralintide against placebo in adults with painful knee osteoarthritis and excess weight.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Key facts
- Where
- Buenos Aires, Granadero Baigorria, Rosario, San Fernando, San Isidro, San Juan, SAN M. de Tucuman, San Miguel de Tucumán, and San Nicolás, ArgentinaSee the 14 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with knee osteoarthritis pain who also have overweight or obesity (BMI of 27 kg/m² or higher) and have not lost weight through diet.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Osteoarthritis of the knee with pain, and at least one of: over 50 years old, morning knee stiffness lasting about 30 minutes, or a crackling or grinding feeling in the knee.
- Earlier treatment
- Must have tried at least once to lose weight through diet without success. Must not have taken weight-loss medications or alternative remedies within 90 days of screening.
- Biomarker or test result
- BMI of 27 kg/m² or higher at screening; stable body weight (less than 5% change) for 90 days before screening.
Main reasons for not taking part
- Any type of diabetes (type 1, type 2 or other)
- Surgery or endoscopic or device-based treatment for obesity (some exceptions if long ago)
- Active knee infection
- Heart attack, stroke, coronary artery revascularization, unstable angina or hospitalization for heart failure within 90 days before screening
- Class IV congestive heart failure (New York Heart Association)
Read by machine on 9 November 2026.
Where in Argentina
- CARDIAMET Investigaciones MédicasBuenos Aires, ArgentinaContact: Virginia Durigan (principal investigator)Not yet recruiting
- Centro Médico ArsemaBuenos Aires, ArgentinaContact: Federico Ariel (principal investigator)Not yet recruiting
- Centro Privado de Medicina Familiar / Mindout ResearchBuenos Aires, ArgentinaContact: Leonardo Naftal (principal investigator)Not yet recruiting
- Organización Médica de InvestigaciónBuenos Aires, ArgentinaContact: Patricio Tate (principal investigator)Not yet recruiting
- Stat Research S.A.Buenos Aires, ArgentinaContact: ALEJANDRO ARROYO (principal investigator)Not yet recruiting
- Centro de Investigaciones Clínicas BaigorriaGranadero Baigorria, ArgentinaContact: Juan Escalante (principal investigator)Not yet recruiting
- INECO Neurociencias OroñoRosario, ArgentinaContact: Florencia Garavelli (principal investigator)Not yet recruiting
- Instituto Especialidades de la Salud RosarioRosario, ArgentinaContact: Julieta Gentiletti (principal investigator)Not yet recruiting
- Medicina ReumatológicaSan Fernando, ArgentinaContact: Maria Cusa (principal investigator)Not yet recruiting
- Instituto de Alta Complejidad San IsidroSan Isidro, ArgentinaContact: Maria Lazaro (principal investigator)Not yet recruiting
- Centro Polivalente de Asistencia E Investigacion Clinica Cer San JuanSan Juan, ArgentinaContact: Rodolfo Pardo Hidalgo (principal investigator)Not yet recruiting
- Centro de Investigaciones Médicas TucumanSAN M. de Tucuman, ArgentinaContact: Walter Spindler (principal investigator)Not yet recruiting
- Centro de Investigaciones ReumatológicasSan Miguel de Tucumán, ArgentinaContact: Luciana Gonzalez Lucero (principal investigator)Not yet recruiting
- Go Centro Medico San NicolásSan Nicolás, ArgentinaContact: Paulina Lanchiotti (principal investigator)Not yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07353931EU 2025-523768-19-00
- Record updated
- 4 November 2026
- Original description
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.Read full original descriptionShow less
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Inclusion: Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening; Have a stable body weight (less than 5% body weight change) for 90 days prior to screening; Have tried at least once to lose weight through diet but were unsuccessful; Have osteoarthritis of the knee and at least one of the following conditions:; Be over 50 years old; Have morning knee stiffness that lasts about 30 minutes; Have a crackling or grinding sound or feeling in the knee.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have an active knee infection; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.